Abstract
Here we investigated the effect of green lipped mussel oil complex (GLMOC) on inflammation and underlying mechanism in lipopolysaccharide stimulated RAW264.7 murine macrophage cells. GLMOC containing green lipped mussel oil (GLMO), olive oil, and vitamin E (10:20:1) can induce significant suppression of iNOS, leading to reduced nitric oxide synthesis, and cyclooxygenase-2, leading to reduced prostaglandin E2 synthesis. In addition, it down-regulated the release of pro-inflammatory cytokines, including tumor necrosis factor-α, interleukin (IL)-6, and IL-1β. Similar to upstream signaling mediators, GLMCO inhibited the degradation of inhibitory κB, nuclear translocation of NF-κB, and phosphorylation of mitogen activated protein kinases (MAPKs) in a dose-dependent manner. Among the components of GLMOC, GLMO was responsible for anti-inflammatory efficacy. Taken together, GLMOC induces anti-inflammatory activity via regulating NF-κB and MAPK signaling in lipopolysaccharide-induced RAW264.7 cells, providing underlying mechanisms that elucidate the anti-inflammatory efficacy of GLMOC.
Similar content being viewed by others
References
Doggrell SA. Lyprinol-is it a useful anti-inflammatory agent? Evid. Based Complement. Alternat. Med. 2011: 307121 (2011)
Cho SH, Jung YB, Seong SC, Park HB, Byun KY, Lee DC, Song EK, Son JH. Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial. Eur. Ann. Allergy. Clin. Immunol. 35: 212–216 (2003)
Gruenwald J, Graubaum HJ, Hansen K, Grube B. Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. Adv. Ther. 21: 197–201 (2004)
Hielm-Bjorkman A, Tulamo RM, Salonen H, Raekallio M. Evaluating complementary therapies for canine osteoarthritis part I: Green-lipped mussel (Perna canaliculus). Evid. Based Complement. Alternat. Med. 6: 365–373 (2009)
Lee CH, Lum JH, Ng CK, McKay J, Butt YK, Wong MS, Lo SC. Pain controlling and cytokine-regulating effects of lyprinol, a lipid extract of Perna canaliculus, in a rat adjuvant-induced arthritis model. Evid. Based Complement. Alternat. Med. 6: 239–245 (2009)
Halpern GM. Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg. Immunol. (Paris) 32: 272–278 (2000)
McPhee S, Hodges LD, Wright PF, Wynne PM, Kalafatis N, Harney DW, Macrides TA. Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculus. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 146: 346–356 (2007)
Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS. Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J. Gastroenterol. 40: 361–365 (2005)
Emelyanov A, Fedoseev G, Krasnoschekova O, Abulimity A, Trendeleva T, Barnes PJ. Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial. Eur. Respir. J. 20: 596–600 (2002)
Mickleborough TD, Vaughn CL, Shei RJ, Davis EM, Wilhite DP. Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. Respir. Med. 107: 1152–1163 (2013)
Dugas B. Lyprinol inhibits LTB4 production by human monocytes. Allerg. Immunol. (Paris) 32: 284–289 (2000)
Medzhitov R. Origin and physiological roles of inflammation. Nature 454: 428–435 (2008)
Laveti D, Kumar M, Hemalatha R, Sistla R, Naidu VG, Talla V, Verma V, Kaur N, Nagpal R. Anti-inflammatory treatments for chronic diseases: a review. Inflamm. Allergy Drug. Targets 12: 349–361 (2013)
Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 36: 1085–1093 (2015)
Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499–511 (2004)
Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 8: 837–848 (2008)
Hawiger J. Innate immunity and inflammation: a transcriptional paradigm. Immunol. Res. 23: 99–109 (2001)
Murakami A, Ohigashi H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int. J. Cancer 121: 2357–2363 (2007)
Grienke U, Silke J, Tasdemir D. Bioactive compounds from marine mussels and their effects on human health. Food Chem. 142: 48–60 (2014)
Shaw CA, Taylor EL, Megson IL, Rossi AG. Nitric oxide and the resolution of inflammation: implications for atherosclerosis. Mem. Inst. Oswaldo Cruz. 100 Suppl. 1: 67–71 (2005)
Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 75: 639–653 (2004)
Echizen K, Hirose O, Maeda Y, Oshima M. Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and toll-like receptor/MyD88 pathways. Cancer Sci. 107: 391–397 (2016)
Esteve JB, Launay-Vacher V, Brocheriou I, Grimaldi A, Izzedine H. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin. Nephrol. 63: 385–389 (2005)
Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat. Rev. Rheumatol. 10: 44–56 (2014)
Lawson BR, Belkowski SM, Whitesides JF, Davis P, Lawson JW. Immunomodulation of murine collagen-induced arthritis by N,N-dimethylglycine and a preparation of Perna canaliculus. BMC Complement. Altern. Med. 7: 20 (2007)
Mitchell S, Vargas J, Hoffmann A. Signaling via the NFkappaB system. Wiley Interdiscip. Rev. Syst. Biol. Med. 8: 227–241 (2016)
Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G, Tsichlis PN. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103: 1071–1083 (2000)
Guma M, Stepniak D, Shaked H, Spehlmann ME, Shenouda S, Cheroutre H, Vicente-Suarez I, Eckmann L, Kagnoff MF, Karin M. Constitutive intestinal NF-kappaB does not trigger destructive inflammation unless accompanied by MAPK activation. J. Exp. Med. 208: 1889–1900 (2011)
Murphy KJ, Mooney BD, Mann NJ, Nichols PD, Sinclair AJ. Lipid, FA, and sterol composition of New Zealand green lipped mussel (Perna canaliculus) and Tasmanian blue mussel (Mytilus edulis). Lipids 37: 587–595 (2002)
Whitehouse MW, Macrides TA, Kalafatis N, Betts WH, Haynes DR, Broadbent J. Anti-inflammatory activity of a lipid fraction (lyprinol) from the NZ green-lipped mussel. Inflammopharmacology 5: 237–246 (1997)
Wakimoto T, Kondo H, Nii H, Kimura K, Egami Y, Oka Y, Yoshida M, Kida E, Ye Y, Akahoshi S, Asakawa T, Matsumura K, Ishida H, Nukaya H, Tsuji K, Kan T, Abe I. Furan fatty acid as an anti-inflammatory component from the green-lipped mussel Perna canaliculus. Proc. Natl. Acad. Sci. USA 108: 17533–17537 (2011)
Acknowledgements
This research was supported by the Chung-Ang University research grant in 2016.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chen, J., Bao, C., Cho, S.H. et al. Green lipped mussel oil complex suppresses lipopolysaccharide stimulated inflammation via regulating nuclear factor-κB and mitogen activated protein kinases signaling in RAW264.7 murine macrophages. Food Sci Biotechnol 26, 815–822 (2017). https://doi.org/10.1007/s10068-017-0091-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10068-017-0091-5